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ABSTRACT 
We designed the synthesis of a small library of 3-substituted-3,6-diazabicyclo[3.1.1]heptanes whose 
affinity on neuronal nicotinic receptors (nAChRs) was evaluated. Among the synthesized 
compounds, the 5-(3,6-diazabicyclo[3.1.1]heptane-3-yl)-N-(2-fluorophenyl)nicotinamide 43 proved 
to be the most interesting compound with 42 Ki value of 10 pM and a very high7/42 selectivity. 
Furthermore, compounds 35, 39 and 43 elicited a selective partial agonist activity for 42 nAChR 
subtype. 
Finally, in this paper we also report the conclusions on the 3,6-diazabicyclo[3.1.1]heptanes as ligands 
for nAChRs, resulting from our consolidated structure activity relationship (SAR) studies on this 
template. 
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1. Introduction 
The activation of ionotropic acetylcholine nicotinic receptors (nAChRs) is responsible for several 
physiological processes; therefore, their modulation could be useful in the treatment of different 
pathological conditions [1]. Due to their potential therapeutic significance, in particular in the frame 
of the fight against tobacco addiction, nAChRs have been the subject of extensive researches that led 
to individuation of bridged piperazines (Figure 1) [2] derived from chemical modification of 
epibatidine, as unusual pharmacophore for nicotinic ligands [3].  
 
 
Figure 1. Bridged piperazines as nAChRs ligands. 
 
The 3,8-diazabicyclo[3.2.1]octane system of 1 (Fig. 1) showed high α4β2 affinity and a potent central 
analgesic activity in mouse hot plate paradigm, in analogy with that of epibatidine. Through 
theoretical calculations and high-field proton magnetic resonance (1H-NMR) spectroscopy resulted 
that the tricyclic system of 1 has one conformation similar to that of epibatidine, responsible of the 
analogy in their pharmacological profile [4]. 
In 2007 were reported the analgesic properties of a novel series of compounds, related to epibatidine, 
among which compound 2 (Figure 1), typified by a 2,5-diazabicyclo[2.2.1]heptane structure, 
represents the best compound of the whole series [5]. Unfortunately, although endowed with 
analgesic activities in several animal models of neuropathic pain, its clinical evaluation was 
precluded, due to its unfavourable pharmacokinetic profile. 
However, this new class of compounds served to hypothesize the common steric and electronic 
features useful to ensure the optimal interactions with nAChR α4β2 and α7, leading to identifying in 
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bridged piperazine bearing a pyridine ring a new pharmacophore model for potential nAChR ligands 
[5]. Starting from the new pharmacophore model of the 2,5-diazabicyclo[2.2.1]heptane core, we 
designed an intriguing structural modification and synthesized a new series of compounds typified 
by a 3,6-diazabicyclo[3.1.1]heptane (3,6-DBH) structure as derivatives 3-8 reported in Figure 2, 
some of which are endowed with an interesting α4β2 subtype receptor profile showing high affinity 
and selectivity [6,7]. 
 
 
Figure 2. 3,6-Diazabicyclo[3.3.1]heptanes. 
 
Among the new synthesized compounds, those with a pyridine bearing a halogen or an aryl 
ring, displayed a spectrum of α4β2 binding affinities comparable to that of epibatidine and the lead 
compound 2. The substitution of an halogen atom in  or  position of the pyridine ring (3, 4, 6 and 
7) seems not to be preferential for the affinity of these compounds; at the same time, the introduction 
of electron-donating and/or electron-withdrawing groups on the aryl ring (8) had minimal effect on 
binding indicating a sensitivity of 42 subtype to positive  values together with negative or positive 
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 values. Moreover, by induced inhibition of [3H]-DA release assay on aryl derivatives, compound 8 
and its analogues proved to be antagonists towards nAChRs [7]. 
Therefore, to further evaluate the structure-activity relationship (SAR) studies on the 3,6-DBH 
structure, we planned the synthesis of new derivatives and the evaluation of their biological profile 
on nAChRs, designing the introduction of different substituted anilines both in the 3- and 2- position 
of the heteroaromatic ring of the pyridinyl-3,6-DBH system, and on its pyridazine analogue, leading 
to compounds 9-11 (Figure 3).  
  
 
Figure 3. Heteroaromatic 3,6-diazabicyclo[3.3.1]heptanes functionalizated. 
 
Within these series, the pharmacomodulation on the heteroaromatic ring linked to 3,6-DBH system 
with different anilines, is responsible for high α4β2 receptor affinity, with Ki ranging from pM to M 
values, and α7/α4β2 selectivity. Indeed, the substitution with different anilines is well tolerated in term 
of receptor affinity, mostly for α4β2 subtype and in minor extent for α3β4, whereas seems harmful for 
α7 receptor subtype, particularly for derivatives of the series typified by 9 [1]. 
To complete the picture on 3,6-DBH ligands, therein we report the synthesis and binding data 
of the new series of compounds, reported in Figure 4 and Table 1, in which we evaluated the effects 
on affinity and selectivity towards different nAChRs, of the introduction of a carboxamidic group 
between the pyridine, on the DBH skeleton, and a second aromatic ring. 
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Figure 4. Related 3,6-diazabicyclo[3.3.1]heptanes. 
 
The resulting structures were also docked to the binding sites of nAChR α7 and α4β2 to evaluate 
possible binding modes and compare them to epibatidine. 
 
2. Results and discussion 
2.1. Chemistry 
The previously reported [7] tert-butyl 3,6-diazabicyclo[3.1.1]heptane-6-carboxylate, 
derivative 12, serves as starting compound for the synthesis of derivatives 32-47. The coupling 
reaction under microwave conditions, between key intermediate 12 and methyl 5-bromonicotinate 
13, led to compound 14, whose hydrolysis (15) followed by acylation with the appropriate anilines 
or amines gave Boc-protected derivatives 16-31. The final N-Boc deprotection yielded compounds 
32-47 (Scheme 1). 
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Scheme 1. Reagents and conditions: a) Cs2CO3, Pd2(dba)3, Xantphos, dioxane, MW (normal abs) 130 
°C, 1-3 h; b) NaOH, H2O, CH3OH, 5 h, 60 °C;  c) amine, EDC, HOBt, DCM, rt, 12 h,; d) HCOOH, 
rt, 12 h. 
 
2.2. nAChR binding affinities  
We synthesized a small library of 5-(3,6-diazabicyclo[3.1.1]heptan-3-yl)-N-
arylnicotinamides (32-47) with the view to test the effect of the introducing a carboxamide group in 
our 3,6-DBH template. Table 1 shows the affinities (Ki) of the newly synthesized compounds towards 
the 42 and 7 nAChR subtypes determined using [3H]-Epibatidine as a ligand for the  42 subtype 
and [125I]α-Bungarotoxin for the 7 subtype.  The Ki values reported in the table are obtained from 
five independent experiments. 
 8 
Most derivatives displayed 7 nAChRs low affinity, ranging in Ki from 1.07 M (33) to > 50 
M (34, 35, 44 and 46). 
First of all, we wanted to evaluate the effect of the anilide group with respect to the carboxamide one 
on the 42 affinity and selectivity of this new series of compounds. Both the introduction of aniline 
ring (32) and benzylamine group (33) in the carboxylic moiety provided good 42 affinity with Ki 
values of 1.1 nM and 1.8 nM, respectively. Due to its better 7/42 selectivity (2182), compound 32 
was chosen as lead compound of the SARs on DBH-nicotinamide series. 
Then, we planned the modulation of the aromatic aniline ring, by inserting a 3-Et (34) and a 3-OCH3 
group (35), whereas the ethyl group maintained the same 42 affinity (Ki = 1.3 nM) with respect to 
32, the introduction of the methoxy group in meta position of the aniline ring (35) led to a slight 
increase of 42 receptors affinity (Ki = 560 pM), resulting both derivatives highly 42 selective (Ki 
7/42 > 38461 and > 89286, respectively). Therefore, was evaluated the effect both of a double 
methoxy group substitution (36, 37) and of the introduction of a 3,4-methylenedioxy functional group 
(38). The latter compound showed a significant increase both in 42 affinity (Ki = 106 pM) and 
selectivity (Ki 7/42 = 79245). 
The most interesting compounds resulted those of the halo-aniline series (39-45). Particularly, 
derivative 43, bearing a 4-fluorine substituted aniline ring, showed the best α4β2 receptor profile with 
a Ki value of 10 pM and a very high selectivity (Ki 7/42 = 3320000). The shift of the fluorine atom 
in meta-position (42), resulted in 4.4-fold loss in α4β2 affinity (Ki = 44 pM) with respect to 43, whereas 
the ortho-monoflourine (41) showed a 31.5-fold loss in α4β2 affinity (Ki = 315 pM). The double 
substitution, to the 2,4-difluorine derivative (44) led to a compound with α4β2 receptor affinity and 
selectivity similar to 42.  
 The introduction of an alogen atom, as chlorine (40) or iodine (45), gave compounds with 
comparable affinity (Ki α4β2 = 404 pM and Ki α4β2 = 366 pM, respectively), whereas the 3-chlorine 
derivative 39 showed α4β2 affinity (Ki = 42 pM) comparable with 3-fluorine analogue. 
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Finally, we incorporated the N-atom of the carboxamide moiety in a 1,2,3,4-tetrahydroquinoline- (46) 
or 1,2,3,4-tetrahydroisoquinoline-bicyclic system (47). This modification led to 42 affinity values 
of 196 pM and 31 pM, respectively. 
 
Table 1.    and 7 nAChR binding affinity for compounds 32-47. 
 
Compound n X Y R 
   
 
(pM) 
CV 
(%)a 
  
 (M) 
CV 
(%) 
Selectivity 
7/42 
32  0 H H H 1100 55 2.4 40 2182 
33  1 H H H 1800 68 1.07 35 594 
34  0 H H 3-Et 1300 60 > 50 - > 38461 
35  0 H H 3-OMe 560 56 > 50 - > 89286 
36  0 H H 3,5-(OMe)2 985 62 43.1 60 43756 
37  0 H H 3,4-(OMe)2 828 63 2.3 20 2778 
38  0 H H 3,4-OCH2O- 106 49 8.4 32 79245 
39  0 H H 3-Cl 42 49 22.9 40 545238 
40  0 H H 4-Cl 404 56 13 35 32178 
41  0 H H 2-F 315 65 3.4 30 10794 
42  0 H H 3-F 44 60 27.9 29 634091 
43  0 H H 4-F 10 91 33.2 42 3320000 
44  0 H H 2,4-F2 51 65 > 50 - > 980392 
45  0 H H 4-I 366 71 23.4 35 63934 
46  0 -(CH2)2- -CH2- H 196 81 > 50 - 255102 
47  1 -CH2- -CH2- H 31 61 1 29 32258 
[3H]-Epib     0.050 12 N.D.c   
[125I]α-BgTxd     N.D.  1.1   
aCoefficient of variation on three independent experiments. b[3H]-Epibatidine. cNot Determined. 
d[125I]α-Bungarotoxin. 
 
The α3β4 nAChRs affinity for selected compounds (Table 2) found that, overall, derivatives with high 
α4β2 affinity displayed α3β4 Ki values in the nM range, as 39 (Ki α3β4 = 59 nM, Ki α4β2 = 42 pM), 42 
(Ki α3β4 = 28 nM, Ki α4β2 = 44 pM), 43 (Ki α3β4 = 81 nM, Ki α4β2 = 10 pM), 44 (Ki α3β4 = 50 nM, Ki 
α4β2 = 51 pM) and 47 (Ki α3β4 = 21 nM, Ki α4β2 = 31 pM). Among these compounds, the 4-fluorine 
derivative, 43, resulted the most 42 selective compound (Ki 34/ Ki 42 = 8100). 
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Table 2. 34 nAChR binding affinity for compounds 32-47. 
 
Compound n X Y R 
34 
 
(nM) 
CV 
(%)a 
Selectivity 
34/42 
32  0 H H H 192 28 174 
33  1 H H H 16  26 889 
34  0 H H 3-Et 306 20 235 
35  0 H H 3-OMe 265 28 473 
36  0 H H 3,5-(OMe)2 2  40 2030 
37  0 H H 3,4-(OMe)2 516 27 623 
38  0 H H 3,4-OCH2O- 113 45 1066 
39  0 H H 3-Cl 59 26 1405 
40  0 H H 4-Cl 123 20 304 
41  0 H H 2-F 102 26 324 
42  0 H H 3-F 28 30 636 
43  0 H H 4-F 81 27 8100 
44  0 H H 2,4-F2 50 65 980 
45  0 H H 4-I 103 37 281 
46  0 -(CH2)2- -CH2- H 62 41 316 
47  1 -CH2- -CH2- H 21 43 677 
[3H]-Epib     0.150 30  
aCoefficient of variation on three independent experiments. b[3H]-Epibatidine.  
 
2.3. Functional analysis on the nAChRs 
Based on the binding data, we selected compounds 35, 39 and 43 for a functional analysis of 
their agonism on human 42 and 34 heteromeric nAChRs (Figure 5). All tested compounds acted 
as partial agonists, being able to elicit inward whole-cell currents in GH4C1 cells transfected with 
human 4 and 2 subunits, with similar EC50 values: 0.6±0.2 M, 1.0±0.2 M and 0.52±0.04 M for 
compounds 35, 39 and 43, respectively. Even the maximal evoked currents were very similar, being 
38±11 %, 37±7 % and 41±1 % of those elicited by 1 mM ACh. All dose-response curves exhibited 
nH<1 (Figure 5). The selectivity of these compounds was confirmed at the functional level, given 
that their agonist effects on human 34 nAChRs were visible only at high concentrations (>1 M), 
with EC50 values >10 M (Figure 5). In particular, compound 39 was never able to elicit currents 
in GH4C1 cells expressing human 34 nAChRs. 
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Figure 5. Partial agonism of compounds 35, 39 and 43 on 42 nAChR. Dose-response relations were 
obtained by applying compounds 35 (A), 39 (B) or 43 (C) to GH4C1 cells transiently transfected with 
cDNA coding for human 4 and 2 subunits () or human 3 and 4 subunits (). The elicited whole-
cell currents were normalized to those evoked by 1 mM ACh. Symbols represent mean±SEM. Solid 
lines represent the best fit to a single Hill equation. The corresponding parameters are: PANEL A, 
I[35]max=38±11 %, nH=0.3, EC50=0.6±0.2 M (n=6 cells); PANEL B, I[39]max=37±7 %, nH=0.3, 
EC50=1.0±0.2 M (n=5); PANEL C, I[43]max=41±1 %, nH=0.9, EC50=0.52±0.04 M (n=10). 
 
2.4. Molecular docking 
 To gain an insight into the possible binding modes for the compounds they were docked to 
the binding sites of both α4β2 and α7. The simulation showed a clear difference in the ligand 
positioning between the two subtypes. In the crystal structure of nAChR α7 epibatidine is shown to 
interact with multiple residues in the binding site, among them Leu106, Gln114, Tyr91 and most 
prominently an ionic interaction between the nitrogen of the azabicycloheptane moiety and Trp145 
and Tyr191 (Figure 6A). Similar interactions occur in the structure of the α4β2 subtype between the 
pyrrolidine nitrogen and Trp156 and Tyr204 (Figure 6B). Compared to epibatidine the novel 
compounds (exemplary shown with compound 43) are turned around in in the binding pocket of the 
α7 subtype, since the bindig site is closed off on the side of the pyridyl and does not allow for larger 
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substitutions. This leads to a loss of the ionic interaction (Figure 7A). On the other hand, in the α4β2 
subtype the compounds align with epibatidine and retain the ionic interaction. This could explain the 
high selectivity of the larger structures. 
 
 
Figure 6. (A) Epibatidine in the binding site of nAChR α7. It forms polar interactions with Leu106 
and Gln114 (pink arrows), an hydrogen bond with Tyr91 (green arrow) and an ionic interaction with 
Trp145 and Tyr191(blue star). (B) Nicotine in the binding site of nAChR α4β2 forming ionic 
interactions with Trp156 and Tyr204. 
 
 
Figure 7. (A) Compound 43 in the binding site of nAChR α7. The molecule forms hydrogen bonds 
with Trp145 and Tyr91, whereas the core structure is turned around and does not form the ionic 
interaction. (B) Compound 43 in the binding site of nAChR α4β2. The key ionic interaction Trp156 
and Tyr204 is retained and the core scaffold aligns with epibatidine. 
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3. Conclusions 
A small library of 5-(3,6-diazabicyclo[3.1.1]heptan-3-yl)-N-arylnicotinamide derivatives have been 
designed. The 12 compounds synthesized and tested in this study, acting as partial agonists, allowed 
us to deepen the SARs on the 3,6-DBH core as template for the synthesis of potent nicotinic α4β2 
receptor ligands, with Ki binding values better than epibatine for all series. The main structural 
features of whole DBH compounds, synthesized by us to today, are below summarized.  
The initial synthesis of derivatives combining the 3,6-DBH system and various halo-pyridines (3, 4, 
6 and 7) and a chloropiridazine (5) furnished compounds endowed with high α4β2 affinity and 
selectivity. This evidence let us to assume the halo-pyridine structure as lead compound and the 5’-
position of the pyridine ring as preferred for the modulation of this system, due to the interesting α4β2 
binding values of agonists 6 and 7, (Ki α4β2 = 6.32 pM and 5.72 pM, respectively).  
The modulation of C-5’ aniline position with various substituted aryls, compounds typified by 
structure 11 (Ki α4β2 = 11.17 pM), displayed high α4β2 receptors affinity in accordance with that of 
halogenated homologues and very high selectivity values, the latter influenced by mono-phenyl 
substitution. Interestingly, the introduction of aryl rings on C-5’ of pyridine nucleus exhibited α4β2 
antagonist activity. 
The introduction of an amine group between the heteroaromatic ring of the DBH system and the aryl 
ring gave three different classes of compounds, typified by compounds 9-11, resulting compounds of 
the 3-(anilino)pyridine series those with the high α4β2 Ki values ranging in the pM field (9, Ki α4β2 = 
11.17 pM) and an affinity and selectivity slightly decreased with respect to the lead compound. 
Finally, the introduction of the N-aryl nicotinamide function, allowed to identify the halo-aryl 
nicotinamides as the best derivatives of this series, resulting the compound 43 having a Ki α4β2 = 10 
pM, similar to that of the lead compound of the whole DBH series. 
In conclusion, tacking stock on 3,6-diazabicyclo[3.1.1]heptane ligands, we can conclude that the 
DBH-pyridine template represents a good pharmacophore for the design of nAChR ligands endowed 
with very high α4β2 affinity and selectivity, influenced by the nature of substituent on pyridine ring. 
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Indeed, even if all tested compound of different DBH series synthesized by us maintain high α4β2 
affinity and selectivity, from our SARs emerged that the  or , both chlorine and bromine, 
substitution on the pyridine ring led to the best compounds of the DBH series with a very high affinity 
and selectivity for α4β2 nAChR subtype, better than epibatidine. 
 
4. Experimental section 
4.1. General procedures 
 The reactions involving air or moisture-sensitive compounds were performed under argon 
atmosphere. Unless otherwise specified, all materials, solvents, reagents and precursors were 
obtained from commercial suppliers and were used without further purification. The standard 
configuration of the Biotage® Microwave Initiator Eight 2.5 was used for microwave experiments, 
which were carried out in sealed microwave process vials under normal absorption. A 4560 Parr 
Apparatus and an H2PEM-100 Parker Balston Hydrogen Generator were used for hydrogenation 
reactions. Purification by flash column chromatography (FC) was performed on Flash-master 
(Biotage®) with pre-packed Biotage® SNAP silica gel cartridges or manually on silica gel (Kieselgel 
60, 0.040−0.063 mm, Merck®). The thin layer chromatography (TLC) was used to monitor reactions 
and was performed with Polygram SIL N-HR/HV254 pre-coated plastic sheets (0.2 mm) on aluminum 
sheets (Kieselgel 60 F254, Merck®).  Melting points were determined on a Köfler melting point 
apparatus and are uncorrected. IR spectra were measured as KBr pallets with a Jasco FT/IR 460 plus 
spectrophotometer and are expressed in  (cm-1). NMR experiments were recorded on a Varian Unity 
200 spectrometer (200.07 MHz for 1H, and 50.31 MHz for 13C, respectively) and the spectra were 
acquired using deuterated chloroform (chloroform-d) as solvent. Chemical shifts () for 1H- and 13C-
NMR spectra are reported in parts per million (ppm) using the residual non-deuterated solvent 
resonance as the internal standard (for chloroform-d: 7.26 ppm, 1H and 77.16 ppm, 13C; for DMSO-
d6: 2.50 ppm, 
1H, 39.52 ppm, 13C). Data are reported as follows: chemical shift, multiplicity (s for 
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singlet, bs for broad singlet, d for doublet, t for triplet, q for quadruplet, qu for quintuplet, m for 
multiplet), integration and coupling constants (J) in Hertz (Hz). All final compounds displayed ≥ 95% 
purity as determined by elemental analysis on a Perkin-Elmer 240-B analyser, for C, H, and N.  
4.1.1. Methyl 5-[6-(tert-butoxycarbonyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl]nicotinate (14) 
To a solution of the Boc-bridged-piperazine 12 (200 mg, 1.00 mmol) [7] in dioxane (5 mL), nicotinic 
bromo-ester 13 (283 mg, 1.31 mmol), Pd2(dba)3 (28 mg, 0.03 mmol), Xantophos (58 mg, 0.10 mmol) 
and Cs2CO3 (657 mg, 2.01 mmol) were added. The mixture was reacted under MW irradiation (12 h, 
110 °C, low abs) and the suspension was filtered on celite®. After in vacuum concentration of the 
filtrate, the resulting residue was dissolved in EtOAc, washed (H2O), dried (Na2SO4) and 
concentrated in vacuum. The title compound 14 was isolated by FC (petroleum ether/EtOAc 5:5) as 
an orange oil. Yield 86% (292 mg, 0,87 mmol). 1H-NMR (200 MHz, CDCl3)  8.62 (s, 1H), 8.29 (s, 
1H), 7.57 (s, 1H), 4.33 (d, 2H, J = 5.4 Hz), 3.80-4.05 (m, 5H), 3.35 (d, 2H, J = 10.0 Hz), 2.60-2.80 
(m, 1H), 1.52 (d, 1H, J = 8.8 Hz), 1.35 (s, 9H). 
4.1.2. 5-[6-(tert-Butoxycarbonyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl]nicotinic acid (15) 
To a solution of the ester 14 (100 mg, 0.30 mmol) in methanol (1.35 mL) a solution of NaOH (394 
mg) in H2O (0.7 mL) was added. The mixture was stirred at room temperature for 2 h, then diluted 
with EtOAc. The aqueous phase was acidified to pH 4 and extracted with CH2Cl2, which was dried 
(Na2SO4), filtered and concentrated in vacuum. Title compound 15 was isolated as a yellow solid. 
Yield 99% (94 mg, 0.30 mmol). Mp = 225-226 °C, 1H-NMR (200 MHz, CDCl3)  8.75 (s, 1H), 8.36 
(s, 1H), 7.73 (s, 1H), 4.35 (d, 2H, J = 5.8 Hz), 3.86-4.15 (m, 2H), 3.38 (d, 2H, J = 10.2 Hz), 2.62 (bs, 
2H, OH exch. with D2O), 1.54 (d, 1H, J = 8.8 Hz), 1.37 (s, 9H). 
4.1.3. General procedure for the synthesis of amides 16-31 
 To a solution of nicotinic acid derived 15 (0.75 mg, 0.235 mmol) in CH2Cl2 (4 ml) EDC (56 
mg, 0.329 mmol), hydroxy-benzotriazole (38 mg, 0.282 mmol) and DMAP (9 mg,0.08 mmol) were 
added. The solution was stirred at room temperature for 2 h, then the required amine (0.282 mmol) 
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was added and the whole stirred at the same temperature for 4-8 h. The organic solution was washed 
(H2O), dried (Na2SO4), filtered and concentrated in vacuum. The analytically pure product was 
isolated by FC as indicated below. 
4.1.4.  N-Phenyl 5-[6-(tert-butoxycarbonyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl]nicotine 
carboxamide (16) 
 Reaction between 15 and aniline gave a crude product whose purification by FC 
(chloroform/methanol 9:1) afforded 16. Pale oil; yield 94% (87 mg); mp 179-182 °C. 1H-NMR (200 
MHz, CDCl3)  8.44 (bs, 1H, NH exch. with D2O), 8.20-8.30 (m, 1H), 7.50-7.73 (m, 2H), 7.30-7.45 
(m, 3H), 7.10-7.18 (m, 1H), 6.62-6.82 (m, 1H), 4.26-4.39 (m, 2H), 3.83-3.96 (m, 2H), 3.35 (d, 2H, J 
= 10.8 Hz), 2.60-2.75 (m, 1H), 1.51 (d, 1H, J = 8.6 Hz), 1.35 (s, 9H). 
4.1.5. N-Benzyl 5-[6-(tert-butoxycarbonyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl]nicotine 
carboxamide (17) 
 Reaction between 15 and benzylamine gave a crude product whose purification by plug 
chromatography (EtOAc) afforded 17. White solid; yield 94% (90 mg); mp 65-67 °C. 1H-NMR (200 
MHz, CDCl3)  8.29 (s, 1H), 8.20-8.25 (m, 1H), 7.48 (s, 1H), 7.27-7.42 (m, 5H), 6.49 (bs, 1H, NH 
exch. with D2O), 4.67 (d, 2H, J = 5.4 Hz), 4.31 (d, 2H, J = 6.0 Hz), 3.80-4.10 (m, 2H), 3.35 (d, 2H, J 
= 11.0 Hz), 2.60-2.80 (m, 1H), 1.51 (d, 1H, J = 8.8 Hz), 1.38 (s, 9H). 
4.1.6. N-(3-Ethylphenyl) 5-[6-(tert-butoxycarbonyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl]nicotine 
carboxamide (18) 
 Reaction between 15 and 3-ethylaniline gave a crude product whose purification by FC 
(petroleum ether/EtOAc 4:6) afforded 18. White solid; yield 94% (93 mg); mp 91-92 °C. 1H-NMR 
(200 MHz, CDCl3)  8.40-8.50 (m, 1H), 8.27 (d, 1H, J = 3.0 Hz), 7.94 (bs, 1H, NH exch. with D2O), 
7.38-7.58 (m, 3H), 7.32 (d, 1H, J = 7.6 Hz), 7.02 (d, 1H, J = 8.2 Hz), 4.32 (d, 2H, J = 6.4 Hz), 3.85-
4.15 (m, 2H), 3.36 (d, 2H, J = 11.0 Hz), 2.60-2.80 (m, 3H), 1.52 (d, 1H, J = 8.4 Hz), 1.35 (s, 9H), 
1.26 (t, 3H, J = 7.4 Hz). 
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4.1.7. N-(3-Methoxyphenyl) 5-[6-(tert-butoxycarbonyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl]nicotine 
carboxamide (19) 
 Reaction between 15 and 3-methoxyaniline gave a crude product whose purification by FC 
(chloroform/methanol 98:2) afforded 19. White solid; yield 97% (97 mg); mp 77-80 °C. 1H-NMR 
(200 MHz, CDCl3)  7.25-7.35 (m, 1H), 7.38-7.50 (m, 1H), 8.04 (bs, 1H, NH exch. with D2O), 7.40-
7.56 (m, 2H), 7.20-7.35 (m, 1H), 7.12 (d, 1H, J = 7.2 Hz), 6.73 (dd, 1H, Jo = 2.8 Hz, Jm = 8.4 Hz), 
4.32 (d, 2H, J = 6.0 Hz), 3.86-4.18 (m, 2H), 3.84 (s, 3H), 3.35 (d, 2H, J = 10.8 Hz), 2.60-2.80 (m, 
1H), 1.52 (d, 1H, J = 8.6 Hz), 1.35 (s, 9H). 
4.1.8. N-(3,5-diMethoxyphenyl) 5-[6-(tert-butoxycarbonyl)-3,6-diazabicyclo[3.1.1]heptan-3-
yl]nicotine carboxamide (20) 
 Reaction between 15 and 3,5-dimethoxyaniline gave a crude product whose purification by 
FC (petroleum ether/EtOAc 4:6) afforded 20. White solid; yield 90% (96 mg); mp 189-191 °C. 1H-
NMR (200 MHz, CDCl3)  8.43 (s, 1H), 8.18-8.30 (m, 2H), 7.56 (bs, 1H, NH exch. with D2O), 6.90-
7.00 (m, 2H), 6.25-6.32 (m, 1H), 4.32 (d, 2H, J = 5.8 Hz), 3.85-4.10 (m, 2H), 3.80 (s, 6H), 3.35 (d, 
2H, J = 10.2 Hz), 2.60-2.80 (m, 1H), 1.52 (d, 1H, J = 8.8 Hz), 1.35 (s, 9H). 
4.1.9. N-(3,4-diMethoxyphenyl) 5-[6-(tert-butoxycarbonyl)-3,6-diazabicyclo[3.1.1]heptan-3-
yl]nicotine carboxamide (21) 
 Reaction between 15 and 3,4-dimethoxyaniline gave a crude product whose purification by 
FC (petroleum ether/EtOAc 3:7) afforded 21. White solid; yield 90% (96 mg); mp 83-84 °C. 1H-
NMR (200 MHz, CDCl3)  8.43 (s, 1H), 8.20-8.35 (m, 1H), 7.91 (bs, 1H, NH exch. with D2O), 7.51 
(s, 2H), 7.00-7.10 (m, 1H), 6.87 (d, 1H, J = 8.6 Hz), 4.33 (d, 2H, J = 5.8 Hz), 3.95-4.20 (m, 2H), 3.93 
(s, 3H), 3.90 (s, 3H), 3.37 (d, 2H, J = 10.8 Hz), 2.60-2.80 (m, 1H), 1.53 (d, 1H, J = 9.0 Hz), 1.36 (s, 
9H). 
4.1.10. N-(3,4-Methylendioxyphenyl) 5-[6-(tert-butoxycarbonyl)-3,6-diazabicyclo[3.1.1]heptan-3-
yl]nicotine carboxamide (22) 
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 Reaction between 15 and 3,4-methylendioxyaniline gave a crude product whose purification 
by FC (petroleum ether/EtOAc 3:7) afforded 22. White solid; yield 93% (96 mg); mp 78-80 °C. 1H-
NMR (200 MHz, CDCl3)  8.41 (s, 1H), 8.18-8.28 (m, 1H), 8.11 (bs, 1H, NH exch. with D2O), 7.52 
(s, 1H), 7.37 (s, 1H), 6.90-7.00 (m, 1H), 6.79 (d, 1H, J = 8.6 Hz), 5.99 (s, 2H), 4.32 (d, 2H, J = 5.6 
Hz), 3.85-4.10 (m, 2H), 3.35 (d, 2H, J = 10.6 Hz), 2.60-2.80 (m, 1H), 1.51 (d, 1H, J = 8.8 Hz), 1.35 
(s, 9H). 
4.1.11. N-(3-Chlorophenyl) 5-[6-(tert-butoxycarbonyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl]nicotine 
carboxamide (23) 
 Reaction between 15 and 3-chloroaniline gave a crude product whose purification by FC 
(chloroform/methanol 98:2) afforded 23. White solid; yield 85% (85 mg); mp 114 °C. 1H-NMR (200 
MHz, CDCl3)  8.38-8.50 (m, 1H), 8.25-8.35 (m, 1H), 7.93 (bs, 1H, NH exch. with D2O), 7.75-7.88 
(m, 1H), 7.45-7.60 (m, 2H), 7.33 (d, 1H, J = 8.4 Hz), 7.16 (d, 1H, J = 7.8 Hz), 4.27-4.48 (m, 2H), 
3.85-4.18 (m, 2H), 3.30-3.50 (m, 2H), 2.60-2.80 (m, 1H), 1.53 (d, 1H, J = 9.0 Hz), 1.38 (s, 9H). 
4.1.12. N-(4-Chlorophenyl) 5-[6-(tert-butoxycarbonyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl]nicotine 
carboxamide (24) 
 Reaction between 15 and 4-chloroaniline gave a crude product whose purification by FC 
(chloroform/methanol 98:2) afford 24. White solid; yield 89% (89 mg); mp 130-132 °C. 1H-NMR 
(200 MHz, CDCl3)  8.35-8.48 (m, 1H), 8.20-8.33 (m, 1H), 7.96 (bs, 1H, NH exch. with D2O), 7.63 
(d, 2H, J = 8.8 Hz), 7.40-7.56 (m, 1H), 7.36 (d, 2H, J = 8.8 Hz), 4.33 (d, 2H, J = 6.4 Hz), 3.85-4.18 
(m, 2H), 3.36 (d, 2H, J = 10.4 Hz), 2.65-2.80 (m, 1H), 1.52 (d, 1H, J = 8.8 Hz), 1.35 (s, 9H). 
4.1.13. N-(2-Fluorophenyl) 5-[6-(tert-butoxycarbonyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl]nicotine 
carboxamide (25) 
 Reaction between 15 and 2-fluoroaniline gave a crude product whose purification by FC 
(petroleum ether/EtOAc 4:6) afforded 25. Yellowish solid; yield 93% (90 mg); mp 111-113 °C. 1H-
NMR (200 MHz, CDCl3)  8.38-8.50 (m, 2H), 8.20-8.35 (m, 1H), 8.14 (bs, 1H, NH exch. with D2O), 
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7.48-7.58 (m, 1H), 7.05-7.28 (m, 3H), 4.33 (d, 2H, J = 5.6 Hz), 3.90-4.10 (m, 2H), 3.37 (d, 2H, J = 
10.6 Hz), 2.60-2.80 (m, 1H), 1.53 (d, 1H, J = 8.8 Hz), 1.36 (s, 9H). 
4.1.14. N-(3-Fluorophenyl) 5-[6-(tert-butoxycarbonyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl]nicotine 
carboxamide (26) 
 Reaction between 15 and 3-fluoroaniline gave a crude product whose purification by FC 
(petroleum ether/EtOAc 3:7) afforded 26. Yellowish solid; yield 94% (91 mg); mp 188-189 °C. 1H-
NMR (200 MHz, CDCl3)  8.43 (s, 1H), 8.27 (s, 1H), 8.19 (bs, 1H, NH exch. with D2O), 7.60-7.75 
(m, 1H), 7.42-7.55 (m, 1H), 7.20-7.40 (m, 2H), 6.80-7.00 (m, 1H), 4.32 (d, 2H, J = 6.4 Hz), 3.85-
4.10 (m, 2H), 3.34 (d, 2H, J = 10.8 Hz), 2.60-2.80 (m, 1H), 1.52 (d, 1H, J = 8.6 Hz), 1.35 (s, 9H). 
4.1.15. N-(4-Fluorophenyl) 5-[6-(tert-butoxycarbonyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl]nicotine 
carboxamide (27) 
 Reaction between 15 and 4-fluoroaniline gave a crude product whose purification by FC 
(petroleum ether/EtOAc 3:7) afforded 27. Yellowish solid; yield 96% (93 mg); mp 193-195 °C. 1H-
NMR (200 MHz, CDCl3)  8.43 (s, 1H), 8.20-8.35 (m, 1H), 8.11 (bs, 1H, NH exch. with D2O), 7.57-
7.70 (m, 2H), 7.45-7.55 (m, 1H), 7.08 (t, 2H, J = 8.8 Hz), 4.33 (d, 2H, J = 6.4 Hz), 3.85-4.15 (m, 2H), 
3.34 (d, 2H, J = 10.4 Hz), 2.60-2.80 (m, 1H), 1.52 (d, 1H, J = 9.0 Hz), 1.35 (s, 9H). 
4.1.16. N-(2,4-diFluorophenyl) 5-[6-(tert-butoxycarbonyl)-3,6-diazabicyclo[3.1.1]heptan-3-
yl]nicotine carboxamide (28) 
 Reaction between 15 and 2,4-difluoroaniline gave a crude product whose purification by FC 
(petroleum ether/EtOAc 3:7) afforded 28. Yellowish solid; yield 95% (92 mg); mp 157-158 °C. 1H-
NMR (200 MHz, CDCl3)  8.25-8.45 (m, 3H), 8.00 (bs, 1H, NH exch. with D2O), 7.52 (s, 1H), 6.85-
7.10 (m, 2H), 4.34 (d, 2H, J = 6.6 Hz), 3.90-4.15 (m, 2H), 3.37 (d, 2H, J = 10.6 Hz), 2.60-2.80 (m, 
1H), 1.52 (d, 1H, J = 9.0 Hz), 1.36 (s, 9H). 
4.1.17. N-(4-Iodophenyl) 5-[6-(tert-butoxycarbonyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl]nicotine 
carboxamide (29)  
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 Reaction between 15 and 4-iodoaniline gave a crude product whose purification by FC 
(petroleum ether/EtOAc 3:7) afforded 29. Beige solid; yield 89% (109 mg); mp 218-219 °C. 1H-NMR 
(200 MHz, CDCl3)  8.44 (s, 2H), 8.22 (d, 1H, J = 3.2 Hz), 7.68 (d, 2H, J = 8.8 Hz), 7.53 (bs, 1H, 
NH exch. with D2O), 7.47 (d, 2H, J = 8.8 Hz), 4.32 (d, 2H, J = 6.0 Hz), 3.85-4.10 (m, 2H), 3.34 (d, 
2H, J = 10.6 Hz), 2.60-2.80 (m, 1H), 1.50 (d, 1H, J = 8.8 Hz), 1.34 (s, 9H). 
4.1.18. N-(1,2,3,4-Tetrahydroisoquinoline) 5-[6-(tert-butoxycarbonyl)-3,6-
diazabicyclo[3.1.1]heptan-3-yl]nicotine carboxamide (30) 
 Reaction between 15 and 1,2,3,4-tetrahydroisoquinoline gave a crude product whose 
purification by FC (petroleum ether/EtOAc 3:7) afforded 30. Beige solid; yield 89% (109 mg); mp 
73-74 °C. 1H-NMR (200 MHz, CDCl3)  8.18-8.25 (m, 1H), 8.09 (s, 1H), 7.15-7.32 (m, 4H), 7.00-
7.10 (m, 1H), 4.80-5.00 (m, 1H), 4.55-4.68 (m, 1H), 4.31 (d, 2H, J = 3.8 Hz), 3.90-4.10 (m, 3H), 
3.60-3.80 (m, 1H), 3.33 (d, 2H, J = 10.6 Hz), 2.81-3.00 (m, 2H), 2.60-2.80 (m, 1H), 1.35-1.55 (m, 
10H). 
4.1.19. N-(1,2,3,4-Tetrahydroquinoline) 5-[6-(tert-butoxycarbonyl)-3,6-diazabicyclo[3.1.1]heptan-
3-yl]nicotine carboxamide (31) 
 Reaction between 15 and 1,2,3,4-tetrahydroquinoline gave a crude product whose purification 
by FC (petroleum ether/EtOAc 3:7) afforded 31. Beige solid; yield 55% (56 mg); mp 85-87 °C. 1H-
NMR (200 MHz, CDCl3)  8.02 (d, 1H, J = 3.2 Hz), 7.73 (s, 1H), 6.80-7.45 (m, 5H), 4.28 (d, 2H, J 
= 5.8 Hz), 3.80-4.00 (m, 3H), 3.40-3.50 (m, 1H), 3.20 (d, 2H, J = 10.6 Hz), 2.83 (t, 2H, J = 6.6 Hz), 
2.60-2.80 (m, 1H), 2.06 (q, 2H, J = 6.6 Hz), 1.48 (d, 1H, J = 8.8 Hz), 1.35 (s, 9H). 
4.1.20. General procedure for the preparation of final compounds 32-47. 
The appropriate tert-butoxycarbonyl derivative (16 – 31) (0.323 mmol) was dissolved in 
HCOOH (2 mL) and the solution was stirred at room temperature for 20 h. Then H2O was added and 
the acid solution was extracted with CHCl3. The aqueous layer was basified with 10% K2CO3 aqueous 
solution and extracted with CHCl3. The organic layer was dried (Na2SO4), filtered and concentrated 
under reduced pressure to afford the analytically pure product. 
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4.1.21. 5-(3,6-Diazabicyclo[3.1.1]heptane-3-yl)-N-(phenyl)nicotinamide (32) 
 Title compound was synthesized starting from 16. Yellowish solid; yield 75% (71 mg); mp 
126-128 °C. 1H-NMR (200 MHz, CDCl3)  8.38-8.50 (m, 1H), 8.20-8.30 (m, 1H), 8.04 (bs, 1H, NH 
exch. with D2O), 7.66 (d, 2H, J = 8.6 Hz), 7.50-7.55 (m, 1H), 7.30-7.47 (m, 2H), 7.12-7.22 (m, 1H), 
3.93 (d, 2H, J = 6.0 Hz), 3.55-3.70 (m, 4H), 2.70-2.90 (m, 1H), 1.58-1.80 (m, 2H, NH exch. with 
D2O). 
13C-NMR (50 MHz, CDCl3)  164.58 (C=O), 137.93 (C), 134.90 (CH), 134.89 (CH), 129.04 
(2 x CH), 124.70 (CH), 120.45 (2 x CH), 116.06 (C), 115.79 (C), 55.78 (2 x CH2), 50.99 (2 x CH), 
31.23 (CH2). IR (nujol) : 3502 (2 x NH), 1651 (C=O). Elemental analysis calculated (%) for 
C17H18N4O: C 69.37, H 6.16, N 19.03. Found: C 69.46, H 6.20, N 19.05. 
4.1.22. 5-(3,6-Diazabicyclo[3.1.1]heptane-3-yl)-N-(benzyl)nicotinamide (33) 
 Title compound was synthesized starting from 17. Yellowish solid; yield 90% (89 mg); mp 
104-105 °C. 1H-NMR (200 MHz, CDCl3)  8.28 (s, 1H), 8.21 (s, 1H), 7.49 (s, 1H), 7.36 (s, 5H), 6.61 
(bs, 1H, NH exch. with D2O), 4.67 (d, 2H, J = 5.4 Hz), 3.93 (d, 2H, J = 5.4 Hz), 3.50-3.70 (m, 4H), 
2.70-2.90 (m, 1H), 1.72 (bs, 1H, NH exch. with D2O), 1. 61 (d, 1H, J = 8.6 Hz). 
13C-NMR (50 MHz, 
CDCl3)  166.31 (C=O), 144.66 (C), 137.99 (C), 134.91 (CH), 130.24 (C), 128.70 (2 x CH), 127.85 
(2 x CH), 127.55 (CH), 118.01 (CH), 115.79 (CH), 55.60 (2 x CH2), 51.06 (2 x CH), 44.05 (CH2), 
31.20 (CH2). IR (nujol) v: 3489 (2 x NH), 1654 (C=O). Elemental analysis calculated (%) for 
C18H20N4O: C 70.11, H 6.57, N 18.17. Found: C 70.20, H 6.52, N 18.20. 
4.1.23. 5-(3,6-Diazabicyclo[3.1.1]heptane-3-yl)-N-(3-ethylphenyl)nicotinamide (34) 
 Title compound was synthesized starting from 18. White solid; yield 92% (96 mg); mp 186-
187 °C. 1H-NMR (200 MHz, CDCl3)  8.42 (s, 1H), 8.23-8.36 (m, 1H), 7.99 (bs, 1H, NH exch. with 
D2O), 7.47-7.65 (m, 2H), 7.45 (s, 1H), 7.32 (d, 1H, J = 7.6 Hz), 7.02 (d, 1H, J = 7.2 Hz), 3.93 (d, 2H, 
J = 6.0 Hz), 3.55-3.78 (m, 4H), 2.70-2.88 (m, 1H), 2.68 (q, 2H, J = 7.3 Hz), 1.63 (d, 1H, J = 9.0 Hz), 
1.55 (bs, 1H, NH exch. with D2O), 1.26 (t, 3H, J = 7.6 Hz). 
13C-NMR (50 MHz, CDCl3)  163.99 
(C=O), 143.43 (CH), 137.68 (C), 135.29 (CH), 133.66 (CH), 129.75 (C), 127.37 (C), 122.53 (CH), 
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119.14 (CH), 117.05 (CH), 114.50 (CH), 112.11 (C), 54.36 (2 x CH2), 49.93 (2 x CH), 30.17 (CH2), 
27.69 (CH3), 14.54 (CH2). IR (nujol) : 3502 (2 x NH), 1651 (C=O). Elemental analysis calculated 
(%) for C19H22N4O: C 70.78, H 6.88, N 17.38. Found: C 70.86, H 6.90, N 17.35. 
4.1.24. 5-(3,6-Diazabicyclo[3.1.1]heptane-3-yl)-N-(3-methoxyphenyl)nicotinamide (35) 
 Title compound was synthesized starting from 19. White solid; yield 87% (91 mg); mp 153-
155 °C. 1H-NMR (200 MHz, CDCl3)  8.38-8.48 (m, 1H), 8.22-8.35 (m, 1H), 7.92 (bs, 1H, NH exch. 
with D2O), 7.48-7.56 (m, 1H), 7.40-7.47 (m, 1H), 7.20-7.38 (m, 1H), 7.12 (d, 1H, J=7.8 Hz), 6.73 
(dd, 1H, Jo=1.4 Hz, Jm=7.8 Hz), 3.95 (d, 2H, J=5.4 Hz), 3.85 (s, 3H), 3.60-3.80 (m, 4H), 2.70-2.90 
(m, 1H), 1.63 (d, 1H, J=8.8 Hz), 1.57 (bs, 1H, NH exch. with D2O). 
13C-NMR (50 MHz, CDCl3)  
164.52 (C=O), 159.95 (CH), 144.83 (C), 139.35 (CH), 134.61 (2 x CH), 130.63 (C), 129.63 (CH), 
116.23 (C), 112.65 (CH), 110.26 (C), 106.25 (CH), 55.48 (2 x CH2), 55.24 (OCH3), 50.83 (2 x CH), 
31.21 (CH2). IR (nujol) : 3505 (2 x NH), 1721 (C=O). Elemental analysis calculated (%) for 
C18H20N4O2: C 66.65, H 6.21, N 17.27. Found: C 66.77, H 6.27, N 17.30. 
4.1.25. 5-(3,6-Diazabicyclo[3.1.1]heptane-3-yl)-N-(3,5-dimethoxyphenyl)nicotinamide (36) 
 Title compound was synthesized starting from 20. White solid; yield 93% (110 mg); mp 216-
219 °C. 1H-NMR (200 MHz, CDCl3)  8.40 (s, 1H), 8.27 (s, 1H), 7.98 (bs, 1H, NH exch. with D2O), 
7.45-7.55 (m, 1H), 6.91 (s, 2H), 6.30 (s, 1H), 3.94 (d, 2H, J = 7.0 Hz), 3.85 (s, 6H), 3.55-3.75 (m, 
4H), 2.70-2.90 (m, 1H), 1.65 (bs, 2H, NH exch. with D2O). 
 13C-NMR (50 MHz, CDCl3)  164.66 (C=O), 160.06 (CH), 143.89 (C), 139.88 (CH), 135.74 (C), 
134.27 (CH), 130.28 (C), 117.58 (CH), 115.16 (C), 98.23 (2 x CH), 95.93 (C), 54.98 (2 x CH2), 54.65 
(2 x OCH3), 50.39 (2 x CH), 30.64 (CH2). IR (nujol) : 3495 (2 x NH), 1721 (C=O). Elemental 
analysis calculated (%) for C19H22N4O3: C 64.39, H 6.26, N 15.81. Found: C 64.45, H 6.29, N 15.83. 
4.1.26. 5-(3,6-Diazabicyclo[3.1.1]heptane-3-yl)-N-(3,4-dimethoxyphenyl)nicotinamide (37) 
 Title compound was synthesized starting from 21. Beige solid; yield 84% (96 mg); mp 204-
205 °C. 1H-NMR (200 MHz, CDCl3)  8.42 (s, 1H), 8.20-8.30 (m, 1H), 8.08 (bs, 1H, NH exch. with 
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D2O), 7.51 (s, 2H), 6.95-7.15 (m, 1H), 6.86 (d, 1H, J = 8.4 Hz), 3.80-4.10 (m, 8H), 3.50-3.70 (m, 
4H), 2.70-2.90 (m, 1H), 1.63 (d, 1H, J = 9.6 Hz), 1.55 (bs, 1H, NH exch. with D2O). 
 13C-NMR (50 MHz, CDCl3)  164.27 (C=O), 148.84 (C), 145.91 (C), 144.83 (C), 134.51 (CH, C), 
131.64 (CH), 117.97 (C), 116.10 (CH), 112.37 (CH), 111.11 (CH), 105.20 (CH), 55.98 (2 x OCH3), 
55.49 (2 x CH2), 50.93 (2 x CH), 31.22 (CH2). IR (nujol) : 3495 (2 x NH), 1721 (C=O). Elemental 
analysis calculated (%) for C19H22N4O3: C 64.39, H 6.26, N 15.81. Found: C 64.45, H 6.30, N 15.86. 
4.1.27. 5-(3,6-Diazabicyclo[3.1.1]heptane-3-yl)-N-(3,4-methylendioxyphenyl)nicotinamide (38) 
 Title compound was synthesized starting from 22. Beige solid; yield 88% (96 mg); mp 201-
202 °C. 1H-NMR (200 MHz, CDCl3)  8.30-8.50 (m, 1H), 8.26 (d, 1H, 3.0 Hz), 7.98 (bs, 1H, NH 
exch. with D2O), 7.45-7.58 (m, 1H), 7.30-7.45 (m, 1H), 6.95 (dd, 1H, Jo = 2.2 Hz, Jm = 8.6 Hz), 6.80 
(d, 1H, J = 8.4 Hz), 5.99 (s, 2H), 3.94 (d, 2H, J = 6.4 Hz), 3.55-3.75 (m, 4H), 2.70-2.90 (m, 1H), 1.58-
1.80 (m, 2H, NH exch. with D2O). 
13C-NMR (50 MHz, CDCl3)  164.49 (C=O), 147.71 (CH), 144.82 
(C), 144.42 (C), 135.73 (2 x CH), 132.25 (C), 130.76 (C), 116.09 (C), 113.76 (CH), 108.05 (CH), 
103.20 (CH), 101.28 (CH2), 55.95 (2 x CH2), 50.91 (2 x CH), 31.22 (CH2). IR (nujol) : 3500 (2 x 
NH), 1723 (C=O). Elemental analysis calculated (%) for C18H18N4O3: C 63.89, H 5.36, N 16.56. 
Found: C 64.01, H 5.40, N 16.60. 
4.1.28. 5-(3,6-Diazabicyclo[3.1.1]heptane-3-yl)-N-(3-chlorophenyl)nicotinamide (39) 
 Title compound was synthesized starting from 23. White solid; yield 97% (103 mg); mp 147-
149 °C. 1H-NMR (200 MHz, CDCl3)  8.35-8.48 (m, 1H), 8.20-8.30 (m, 1H), 8.11 (bs, 1H, NH exch. 
with D2O), 7.81 (s, 1H), 7.38-7.58 (m, 2H), 7.33 (d, 1H, J = 7.8 Hz), 7.15 (d, 1H, J = 7.8 Hz), 3.87-
4.10 (m, 2H), 3.50-3.80 (m, 4H), 2.70-2.90 (m, 1H), 1.60-1.90 (m, 2H, NH exch. with D2O). 
13C-
NMR (50 MHz, CDCl3)  164.79 (C=O), 143.90 (C), 139.49 (CH), 135.75 (C), 134.38 (C), 133.32 
(CH), 130.02 (C), 129.13 (CH), 123.28 (CH), 119.95 (CH), 118.10 (CH), 115.23 (CH), 54.97 (2 x 
CH2), 50.33 (2 x CH), 30.58 (CH2). IR (nujol) : 3503 (2 x NH), 1654 (C=O). Elemental analysis 
calculated (%) for C17H17ClN4O: C 62.10, H 5.21, N 17.04. Found: C 62.23, H 5.29, N 17.11. 
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4.1.29. 5-(3,6-Diazabicyclo[3.1.1]heptane-3-yl)-N-(4-chlorophenyl)nicotinamide (40) 
 Title compound was synthesized starting from 24. White solid; yield 86% (91 mg); mp 188-
190 °C. 1H-NMR (200 MHz, CDCl3)  8.36-8.48 (m, 1H), 8.20-8.32 (m, 1H), 7.93 (bs, 1H, NH exch. 
with D2O), 7.63 (d, 2H, J = 8.8 Hz), 7.45-7.55 (m, 1H), 7.36 (d, 2H, J = 8.8 Hz), 3.90-4.10 (m, 2H), 
3.62-3.68 (m, 4H), 2.78-2.90 (m, 1H), 1.60-1.85 (m, 2H, NH exch. with D2O). 
13C-NMR (50 MHz, 
CDCl3)  164.29 (C=O), 143.56 (C), 141.23 (C), 136.74 (CH), 135.48 (CH), 134.06 (C), 129.97 (C), 
127.52 (3 x CH), 121.02 (2 x CH), 54.68 (2 x CH2), 49.93 (2 x CH), 30.23 (CH2). IR (nujol) : 3503 
(2 x NH), 1654 (C=O). Elemental analysis calculated (%) for C17H17ClN4O: C 62.10, H 5.21, N 17.04. 
Found: C 62.23, H 5.24, N 17.12. 
4.1.30. 5-(3,6-Diazabicyclo[3.1.1]heptane-3-yl)-N-(2-fluorophenyl)nicotinamide (41) 
 Title compound was synthesized starting from 25. White solid; yield 85% (85 mg); mp 86-87 
°C. 1H-NMR (200 MHz, CDCl3)  8.38-8.55 (m, 2H), 8.25-8.35 (m, 1H), 8.09 (bs, 1H, NH exch. 
with D2O), 7.10-7.35 (m, 3H), 3.96 (d, 2H, J = 5.6 Hz), 3.60-3.80 (m, 4H), 2.70-2.90 (m, 1H), 1.55-
1.78 (m, 2H, NH exch. with D2O). 
13C-NMR (50 MHz, CDCl3)  165.01 (C=O), 143.90 (CH), 137.23 
(CH), 136.23 (C), 135.57 (CH), 135.22 (C), 130.22 (C), 125.26 (CH), 125.03 (C), 124.31 (CH), 
116.38 (CH), 115.61 (CH), 56.95 (2 x CH2), 49.27 (2 x CH), 30.15 (CH2). IR (nujol) : 3506 (2 x 
NH), 1684 (C=O). Elemental analysis calculated (%) for C17H17FN4O: C 65.37, H 5.49, N 17.94. 
Found: C 65.43, H 5.51, N 17.90. 
4.1.31. 5-(3,6-Diazabicyclo[3.1.1]heptane-3-yl)-N-(2-fluorophenyl)nicotinamide (42) 
 Title compound was synthesized starting from 26. Yellowish solid; yield 87% (87 mg); mp 
208-210 °C. 1H-NMR (200 MHz, CDCl3)  8.41 (s, 1H), 8.25-8.33 (m, 1H), 8.03 (bs, 1H, NH exch. 
with D2O), 7.60-7.75 (m, 1H), 7.45-7.56 (m, 1H), 7.25-7.38 (m, 2H), 6.85-6.98 (m, 1H), 3.95 (d, 2H, 
J = 5.6 Hz), 3.55-3.70 (m, 4H), 2.70-2.90 (m, 1H), 1.55-1.80 (m, 2H, NH exch. with D2O). 
13C-NMR 
(50 MHz, CDCl3)  164.20 (C=O), 143.36 (C), 139.60 (C), 135.18 (CH), 133.83 (CH), 129.43 (CH), 
128.49 (C), 114.86 (CH), 114.47 (CH), 112.06 (CH), 106.74 (CH), 106.23 (C), 54.33 (2 x CH2), 
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49.79 (2 x CH), 30.09 (CH2). IR (nujol) : 3505 (2 x NH), 1684 (C=O). Elemental analysis calculated 
(%) for C17H17FN4O: C 65.37, H 5.49, N 17.94. Found: C 65.45, H 5.54, N 17.89. 
4.1.32. 5-(3,6-Diazabicyclo[3.1.1]heptane-3-yl)-N-(4-fluorophenyl)nicotinamide (43) 
 Title compound was synthesized starting from 27. White solid; yield 87% (87 mg); mp 250-
252 °C. 1H-NMR (200 MHz, CDCl3)  8.41 (s, 1H), 8.29 (s, 1H), 7.86 (bs, 1H, NH exch. with D2O), 
7.58-7.70 (m, 2H), 7.50-7.56 (m, 1H), 7.09 (d, 2H, J = 8.4 Hz), 3.90-4.00 (m, 2H), 3.62-3.79 (m, 4H), 
2.70-2.90 (m, 1H), 1.50-1.80 (m, 2H, NH exch. with D2O). 
13C-NMR (50 MHz, CDCl3)  164.68 
(C=O), 144.50 (C), 136.18 (C), 135.12 (2 x C), 135.08 (CH), 130.33 (CH), 122.46 (CH), 122.44 
(CH), 115.55 (CH), 115.15 (2 x CH), 54.97 (2 x CH2), 50.22 (2 x CH), 30.64 (CH2). IR (nujol) : 
3505 (2 x NH), 1684 (C=O). Elemental analysis calculated (%) for C17H17FN4O: C 65.37, H 5.49, N 
17.94. Found: C 65.49, H 5.52, N 17.89. 
4.1.33. 5-(3,6-Diazabicyclo[3.1.1]heptane-3-yl)-N-(2,4-difluorophenyl)nicotinamide (44) 
 Title compound was synthesized starting from 28. Beige solid; yield 86% (92 mg); mp 193-
194 °C. 1H-NMR (200 MHz, CDCl3)  8.25-8.45 (m, 3H), 7.99 (bs, 1H, NH exch. with D2O), 7.40-
7.60 (m, 1H), 6.80-7.05 (m, 2H), 3.95 (d, 2H, J = 6.0 Hz), 3.60-3.80 (m, 4H), 2.70-2.90 (m, 1H), 1.64 
(d, 1H, J = 9.0 Hz), 1.50 (bs, 1H, NH exch. with D2O). 
13C-NMR (50 MHz, CDCl3)  164.62 (C=O), 
160.12 (C), 157.67 (C), 154.19 (C), 151.73 (C), 144.90 (CH), 135.90 (CH), 134.85 (CH), 130.30 
(CH), 123.29 (CH), 122.43 (C), 115.53 (CH), 55.72 (2 x CH2), 51.24 (2 x CH), 31.35 (CH2). 
IR (nujol) : 3502 (2 x NH), 1662 (C=O). Elemental analysis calculated (%) for C17H16F2N4O: C 
61.81, H 4.88, N 16.96. Found: C 61.95, H 4.91, N 16.90. 
4.1.34. 5-(3,6-Diazabicyclo[3.1.1]heptane-3-yl)-N-(4-iodophenyl)nicotinamide (45) 
 Title compound was synthesized starting from 29. Yellowish solid; yield 86% (117 mg); mp 
238-240 °C. 1H-NMR (200 MHz, CDCl3)  8.40 (s, 1H), 8.27 (d, 1H, J = 3.0 Hz), 8.10 (bs, 1H, NH 
exch. with D2O), 7.69 (d, 2H, J = 8.8 Hz), 7.46 (d, 2H, J = 8.8 Hz), 3.93 (d, 2H, J = 6.0 Hz), 3.50-
3.70 (m, 4H), 2.70-2.90 (m, 1H), 1.55-1.80 (m, 2H, NH exch. with D2O). 
13C-NMR (50 MHz, CDCl3) 
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 164.48 (C=O), 143.70 (C), 137.97 (C), 136.56 (2 x CH), 134.15 (C), 134.14 (CH), 121.82 (2 x CH), 
117.44 (CH), 114.89 (CH), 86.41 (C), 54.72 (2 x CH2), 50.23 (2 x CH), 32.28 (CH2). IR (nujol) : 
3507 (2 x NH), 1693 (C=O). Elemental analysis calculated (%) for C17H17IN4O: C 48.59, H 4.08, N 
13.33. Found: C 48.69, H 4.15, N 13.38. 
4.1.35. 5-(3,6-Diazabicyclo[3.1.1]heptane-3-yl)-N-(1,2,3,4-tetrahydroisoquinoline)nicotinamide 
(46) 
 Title compound was synthesized starting from 30. Yellowish solid; yield 73% (79 mg); mp 
157-160 °C. 1H-NMR (200 MHz, CDCl3)  8.22 (d, 1H, J = 3.2 Hz), 8.10 (s, 1H), 7.10-7.45 (m, 4H), 
7.07 (s, 1H), 4.91 (s, 1H), 4.60-4.75 (m, 1H), 3.85-4.15 (m, 3H), 3.45-3.80 (m, 5H), 2.70-3.10 (m, 
3H), 1.40-1.70 (bs, 2H, NH exch. with D2O). 
13C-NMR (50 MHz, CDCl3)  168.79 (C=O), 143.91 
(CH), 143.68 (CH), 134.49 (C), 133.92 (CH), 132.61 (CH), 132.47 (CH), 132.07 (C), 127.06 (C), 
126.73 (2 x CH), 115.41 (C), 58.16 (2 x CH2), 57.54 (2 x CH), 48.01 (CH2), 45.43 (CH2), 44.82 
(CH2), 29.68 (CH2). IR (nujol) : 3421 (NH), 1719 (C=O). Elemental analysis calculated (%) for 
C20H22N4O: C 71.83, H 6.63, N 16.75. Found: C 71.92, H 6.70, N 16.80. 
4.1.36. 5-(3,6-Diazabicyclo[3.1.1]heptane-3-yl)-N-(1,2,3,4-tetrahydroquinoline)nicotinamide (47) 
 Title compound was synthesized starting from 31. White solid; yield 81% (87 mg); mp 57-58 
°C. 1H-NMR (200 MHz, CDCl3)  8.08 (s, 1H), 7.79 (s, 1H), 6.87-7.20 (m, 4H), 6.70-6.80 (m, 1H), 
3.85-3.96 (m, 4H), 3.45-3.55 (m, 4H), 2.86 (d, 2H, J = 6.4 Hz), 2.74-2.82 (m, 1H), 2.07 (qu, 2H, J = 
6.4 Hz), 1.58-1.78 (bs, 1H, NH exch. with D2O), 1.61 (d, 1H, J = 8.8 Hz). 
13C-NMR (50 MHz, CDCl3) 
 168.50 (C=O), 146.61 (CH), 145.68 (CH), 137.49 (C), 134.02 (CH), 133.69 (CH), 133.47 (CH), 
131.87 (C), 127.06 (C), 125.73 (2 x CH), 115.41 (C), 57.16 (2 x CH2), 55.57 (2 x CH), 49.15 (CH2), 
46.43 (CH2), 44.86 (CH2), 24.68 (CH2). IR (nujol) : 3421 (NH), 1719 (C=O). Elemental analysis 
calculated (%) for C20H22N4O: C 71.83, H 6.63, N 16.75. Found: C 71.90, H 6.71, N 16.83. 
 
4.2. Binding studies 
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The affinities (Ki) of the synthetized compounds for the 42,   and 7 receptors were 
determined as previously described [1] using [3H]-Epibatidine labeled rat cerebral cortex membranes 
(42), or  membranes of HEK 243 cells transiently trasfected with  human     nAChR,  [125I] -
Bungarotoxin labelled rat hippocampus membranes (7).  
The Ki (% of coefficient of variation) values shown were calculated by using the LIGAND 
program to fit the data obtained from at least three independent saturation and competition binding 
experiments for each compound using the α4β2, α3β4, and α7 subtypes.  
 
4.3. Functional activity. 
The electrophysiological measurements were made as previously described [8]. 
 
4.4. Molecular docking. 
 The docking simulations were performed with GOLD version 5.2 (Cambridge 
Crystallographic Data Centre, Cambridge, UK). This program uses a genetic algorithm to calculate 
up to ten docking poses per input-ligand. GoldScore Fitness was selected as a scoring function, which 
takes hydrogen bonding, ligand internal strains, and steric aspects of the receptor-ligand complex into 
account. 
Docking simulations were conducted on nAChR α4β2 and α7 subtypes. For the α7 subtype a crystal 
structure co-crystallized with epibatidine was available (PDB entry 3SQ6) [9] and used for docking. 
A redocking was conducted to optimize the docking parameters and led to an RMSD of 1.18 with the 
final settings. In the course of the protein preparation, hydrogens were added. The binding site was 
defined in a 8 Å radius around the co-crystallized ligand of chain A. 
For the α7 subtype a crystal structure co-crystallized with epibatidine was available (PDB entry 3SQ6) 
and used for docking. A redocking was conducted to optimize the docking parameters and led to an 
RMSD of 1.18 with the final settings. In the course of the protein preparation, hydrogens were added. 
The binding site was defined in a 8 Å radius around the co-crystallized ligand of chain A. 
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For the α4β2 subtype a crystal structure co-crystallized with nicotine was used (PDB entry 5KXI) 
[10], since the substrate is similar in size to epibatidine. A redocking of nicotine resulted in an RMSD 
of 1.22 with the final settings. In the course of the protein preparation, hydrogens were added. The 
binding site was also defined in a 8 Å radius around the co-crystallized ligand of chain A to keep the 
settings similar to the settings used in the docking on the α7 subtype. 
 
Appendix A. Supplementary data 
1H-NMR and 13C-NMR spectra of of representative compounds 35, 39, and 43 are available. 
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